Hallervorden‐Spatz disease: Historical case presentation in the spotlight of nosological evolution

Baron Dr. Ludo van Bogaert (1897–1989) authored more than 700 publications, gave countless lectures at Belgian and foreign universities and at international congresses, and trained more than 300 specialists from all over the world in the Bunge Institute. He filmed many of his patients suffering from movement disorders. Hallervorden‐Spatz disease (HSD) was first described in 1922. The recognition of this well‐defined syndrome was followed by several case reports published and in 1936, a new case was reported by Ludo van Bogaert and Clovis Vincent. To the best of our knowledge, this case report can be considered as the first filmed case of HSD. © 2010 Movement Disorder Society

[1]  P. Rose.  Pigmentary disorders. , 2021, The Medical clinics of North America.

[2]  D. Auer,et al.  The eye-of-the-tiger sign is not a reliable disease marker for Hallervorden-Spatz syndrome. , 2005, Neuropediatrics.

[3]  E. Baeck.  Ludo van Bogaert (1897–1989) and the Bunge Institute , 2005, European journal of neurology.

[4]  P. Brundin,et al.  Harnessing endogenous stem cells to treat neurodegenerative disorders of the basal ganglia. , 2004, Parkinsonism & related disorders.

[5]  S. Hayflick.  Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase–associated neurodegeneration is the name . . . , 2003, Current opinion in pediatrics.

[6]  A. Chiò,et al.  Arthur Van Gehuchten takes neurology to the movies , 2003, Neurology.

[7]  J. Geiderman.  Hallervorden and history. , 2003, The New England journal of medicine.

[8]  Ya Ke,et al.  Iron misregulation in the brain: a primary cause of neurodegenerative disorders , 2003, The Lancet Neurology.

[9]  B. Levinson,et al.  Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. , 2003, The New England journal of medicine.

[10]  Shawn K. Westaway,et al.  A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome , 2001, Nature Genetics.

[11]  M. Shevell,et al.  Julius Hallervorden's wartime activities: implications for science under dictatorship. , 2001, Pediatric neurology.

[12]  T. Taylor,et al.  Homozygosity mapping of Hallervorden–Spatz syndrome to chromosome 20p12.3–p13 , 1996, Nature Genetics.

[13]  M. Shevell.  Racial hygiene, active euthanasia, and Julius Hallervorden , 1992, Neurology.

[14]  M. Patterson,et al.  Hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP syndrome) , 1992, Neurology.

[15]  D. Loring,et al.  Hallervorden‐spatz syndrome: Clinical and magnetic resonance imaging correlations , 1988, Annals of neurology.

[16]  D. Perl,et al.  Adult onset Hallervorden-Spatz disease with neurofibrillary pathology. A discrete clinicopathological entity. , 1987, Brain : a journal of neurology.

[17]  S. Kish,et al.  Hallervorden‐Spatz disease: Cysteine accumulation and cysteine dioxygenase deficiency in the globus pallidus , 1985, Annals of neurology.

[18]  F. Gallyas,et al.  A study of iron metabolism in neuropsychiatric patients. Hallervorden-Spatz disease. , 1966, Archives of neurology.

[19]  J. Hallervorden,et al.  Eigenartige erkrankung im extrapyramidalen system mit besonderer beteiligung des globus pallidus und der substantia nigra , 1922 .

[20]  R. Tripathi,et al.  Clinicopathologic correlation and pathogenesis of ocular and central nervous system manifestations in Hallervorden-Spatz syndrome , 2004, Acta Neuropathologica.

[21]  A. Ieshima,et al.  [Hallervorden-Spatz disease]. , 2001, Ryoikibetsu shokogun shirizu.

[22]  W. Seidelman.  Medicine and murder in the Third Reich. , 1999, Dimensions.

[23]  N. Yanagisawa,et al.  Clinico-pathological and histochemical studies of Hallervorden-Spatz disease with torsion dystonia with special reference to diagnostic criteria of the disease from the clinico-pathological viewpoint. , 1966, Progress in brain research.